Cardiovascular profile of loratadine.

Cardiovascular profile of loratadine.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1999-08-12)

J A Hey, M Affrime, B Cobert, W Kreutner, F M Cuss

ZUSAMMENFASSUNG

The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.

MATERIALIEN

Produktnummer

Marke

Produktbeschreibung

L9664

Sigma-Aldrich

Loratadin, ≥98% (HPLC), powder

1370270

USP

Loratadin, United States Pharmacopeia (USP) Reference Standard

PHR1376

Supelco

Loratadin, Pharmaceutical Secondary Standard; Certified Reference Material

Y0000603

Loratadin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

Y0000688

Loratadin, European Pharmacopoeia (EP) Reference Standard